Syndicate this blog

Archives

Posted 2006-11-03 00:23:08

The results of a clinical study comparing Isovue®-370 (iopamidol injection), marketed by Bracco Diagnostics Inc. in the United States, and Visipaque™-320 (iodixanol injection), marketed by GE Healthcare in the United States, in renally Impaired Patients undergoing Computed Tomography (IMPACT) showed no significant difference in the rate of contrast-induced nephropathy (CIN) between the two agents.

Share this link?   Digg   Reddit   Del.icio.us